Template:Methyldopa: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
 
(One intermediate revision by the same user not shown)
Line 2: Line 2:
! style="padding: 0 5px; font-size: 100%; background:#F8F8FF" align=center | '''''[[Methyldopa|{{fontcolor|#6C7B8B|Methyldopa}}]]'''''
! style="padding: 0 5px; font-size: 100%; background:#F8F8FF" align=center | '''''[[Methyldopa|{{fontcolor|#6C7B8B|Methyldopa}}]]'''''
|-
|-
! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | METHYLDOPA tablet<sup>®</sup> FDA Package Insert
! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | Methyldopa tablet<sup>®</sup> FDA Package Insert
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Methyldopa tablet indications and usage|Indications and Usage]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Methyldopa tablet indications and usage|Indications and Usage]]
Line 8: Line 8:
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Methyldopa tablet dosage and administration|Dosage and Administration]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Methyldopa tablet dosage and administration|Dosage and Administration]]
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Methyldopa tablet dosage forms and strengths|Dosage Forms and Strengths]]
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Methyldopa tablet contraindications|Contraindications]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Methyldopa tablet contraindications|Contraindications]]
Line 29: Line 28:
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Methyldopa tablet nonclinical toxicology|Nonclinical Toxicology]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Methyldopa tablet nonclinical toxicology|Nonclinical Toxicology]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Methyldopa tablet clinical studies|Clinical Studies]]
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Methyldopa tablet how supplied storage and handling|How Supplied/Storage and Handling]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Methyldopa tablet how supplied storage and handling|How Supplied/Storage and Handling]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Methyldopa tablet patient counseling information|Patient Counseling Information]]
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Methyldopa tablet labels and packages|Labels and Packages]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Methyldopa tablet labels and packages|Labels and Packages]]
|-
|-
! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | METHYLDOPA injection<sup>®</sup> FDA Package Insert
! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | Methyldopa injection<sup>®</sup> FDA Package Insert
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Methyldopa injection indications and usage|Indications and Usage]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Methyldopa injection indications and usage|Indications and Usage]]
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Methyldopa injection dosage and administration|Dosage and Administration]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Methyldopa injection dosage and administration|Dosage and Administration]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Methyldopa injection dosage forms and strengths|Dosage Forms and Strengths]]
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Methyldopa injection contraindications|Contraindications]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Methyldopa injection contraindications|Contraindications]]
Line 65: Line 58:
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Methyldopa injection nonclinical toxicology|Nonclinical Toxicology]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Methyldopa injection nonclinical toxicology|Nonclinical Toxicology]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Methyldopa injection clinical studies|Clinical Studies]]
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Methyldopa injection how supplied storage and handling|How Supplied/Storage and Handling]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Methyldopa injection how supplied storage and handling|How Supplied/Storage and Handling]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Methyldopa injection patient counseling information|Patient Counseling Information]]
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Methyldopa injection labels and packages|Labels and Packages]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Methyldopa injection labels and packages|Labels and Packages]]

Latest revision as of 02:36, 13 March 2014